Literature DB >> 24728166

Evaluation of effectiveness and outcome of PKU screening and management in the State of Sergipe, Brazil.

Antônio R O Ramalho1, Roberto J R Ramalho1, Carla R P Oliveira1, Marta M G S Magalhães1, Elenilde G Santos1, Polyana M P Sarmento1, Diana O Matos1, Mario C P Oliveira1, André L P Oliveira1, Manuel H Aguiar-Oliveira1.   

Abstract

OBJECTIVES: Phenylketonuria (PKU) was the first inherited metabolic disease known to cause mental retardation for which a newborn screening program (NBS) was developed. The objective of this study was to evaluate the effectiveness of PKU NBS and the management of cases in the northeastern Brazilian state of Sergipe (SE).
MATERIALS AND METHODS: We reviewed the phenylalanine concentrations in filter-paper collected from the heel (PKUneo) of 43,449 newborns; blood concentrations obtained by venipuncture in the subjects with abnormal PKUneo; the children's age at several phases of the program, the incidence of the disease from January 2007 to June 2008; and metabolic control of the patients.
RESULTS: The coverage of NBS/SE was 78.93%. The children's age was 10 ± 7 days at PKUneo collection. Twelve children were recalled based on the PKUneo cutoff value at 28 ± 13 days. From these, the concentrations of phenylalanine collected by venipuncture were normal in five children. The incidence of hyperphenylalaninemia was 1/43,449, and of PKU was 1/8,690 (5 cases). One suspected subject died. Another death occurred in the cohort, in a confirmed PKU case. PKU treatment began within 51 ± 12 days of life. In the four patients under dietary phenylalanine restriction, metabolic control was often difficult.
CONCLUSIONS: PKU NBS/SE has satisfactory coverage and adequate cutoff for recalling patients and diagnosis, but the onset of treatment is delayed, and follow-up metabolic control is frequently inadequate.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24728166     DOI: 10.1590/0004-2730000002885

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN: 0004-2730


  4 in total

1.  Birth prevalence of phenylalanine hydroxylase deficiency: a systematic literature review and meta-analysis.

Authors:  Pamela K Foreman; Andrea V Margulis; Kimberly Alexander; Renee Shediac; Brian Calingaert; Abenah Harding; Manel Pladevall-Vila; Sarah Landis
Journal:  Orphanet J Rare Dis       Date:  2021-06-03       Impact factor: 4.123

2.  Global prevalence of classic phenylketonuria based on Neonatal Screening Program Data: systematic review and meta-analysis.

Authors:  Hamid Reza Shoraka; Ali Akbar Haghdoost; Mohammad Reza Baneshi; Zohre Bagherinezhad; Farzaneh Zolala
Journal:  Clin Exp Pediatr       Date:  2020-02-06

3.  Lifetime Cost Effectiveness of Phenylketonuria Screening National Program in Iran.

Authors:  Alireza Heidari; Mohammad Arab; Behzad Damari
Journal:  Iran J Public Health       Date:  2021-10       Impact factor: 1.429

4.  Quality of life and adherence to treatment in early-treated Brazilian phenylketonuria pediatric patients.

Authors:  E Vieira; H S Maia; C B Monteiro; L M Carvalho; T Tonon; A P Vanz; I V D Schwartz; M G Ribeiro
Journal:  Braz J Med Biol Res       Date:  2017-12-11       Impact factor: 2.590

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.